Decadron (dexamethasone) tablets are expected to be available sometime in early 2018, according to a press release from Pragma Pharmaceuticals.
Decadron is a first-generation adrenocortical steroid primarily used for its anti-inflammatory effects in disorders of many organ systems, including allergic states, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, neurologic disorders, ophthalmic disorders, renal diseases, respiratory diseases, and rheumatic disorders.
Decadron will be available as 0.5mg, 0.75mg, 4mg, and 6mg strength tablets. The sales and marketing for Decadron will be managed by Fera Pharmaceuticals.
For more information visit FeraPharma.com.